Objective to investigate the protective effects of calcitonin on cKd-mineral and bone disorder, cKd-MBd. Methods 48 cases of hemodialysis patients from august 2011 to august 2013 were selected as research subjects, and were divided into the control group (26 cases) and the observation group (22 cases). Patients of the control group took calcium carbonate 1.0g tid and calcitriol 0.25 g qd, while the observation group were added with calcitonin 20U, 3 times / week (subcutaneous injection, in conventional hemodialysis). all patients lumbar spine and femoral neck BMd in 3,6,12 months were detected. patients pain were recorded using a visual analog pain scale (Vas),the extent and adverse reactions also were recorded. Results Patients lumbar spine, femoral neck bone mineral density after treatment 3,6 months and before treatment did not change significantly, but 12 months after treatment has improved,(P <0.05). two groups of patients after treatment to alleviate pain by degree and VAS have decreased significantly, the difference was statistically significant (P <0.05); in addition to individual patients were observed mild gastrointestinal reactions, other patients were no adverse reactions. Conclusion Calcitonin can significantly promote CKD-MBD in patients, is worthy of clinical use.%目的：探讨降钙素在慢性肾脏病矿物质及骨代谢紊乱患者治疗中的应用效果。方法选择2011年8月至2013年8月来我院接受治疗的48例维持性血液透析患者作为研究对象，将其分为对照组（26例）和观察组（22例），对照组患者常规服用碳酸钙1.0g tid 以及骨化三醇0.25g qd,观察组患者在此基础上加用降钙素20U，3次/周（皮下注射，常规血液透析时使用）。所有患者在治疗前及治疗后3、6、12个月时检测股骨颈骨、腰椎密度，并采用视觉模拟疼痛评分（Vas）记录患者骨痛程度和不良反应。结果患者腰椎、股骨颈骨密度治疗后3、6月和治疗前变化不显著，但治疗后12个月有所好转，其中观察组和对照组相比更加显著（P<0.05）；两组患者治疗后骨痛程度都有所减轻，Vas显著下降，差异具有统计学意义（P<0.05）；除了观察组患者有个别出现轻微消化道反应外，其他患者无不良反应出现。结论降钙素能够显著促进慢性肾脏病矿物质及骨代谢紊乱患者的治疗效果，值得临床推广使用。
展开▼
